TG Therapeutics(CH:NKB2)
CH:NKB2
TG Therapeutics ownership
TG Therapeutics (NKB2) Ownership - Who Owns TG Therapeutics?
0 Followers
TG Therapeutics (NKB2) Ownership Overview
- 7.63% Insiders
- 20.04% Mutual Funds
- 4.80% Other Institutional Investors
- 27.20% ETFs
- 40.34% Public Companies and Individual Investors
The ownership structure of TG Therapeutics (CH:NKB2) stock is a mix of institutional, retail, and individual investors. Approximately 52.03% of the company’s stock is owned by Institutional Investors, 7.63% is owned by Insiders, and 40.34% is owned by Public Companies and Individual Investors.
The ownership structure of TG Therapeutics (CH:NKB2) stock is a mix of institutional, retail, and individual investors. Approximately 52.03% of the company’s stock is owned by Institutional Investors, 7.63% is owned by Insiders, and 40.34% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Sep 13, 2026 | Laurence Charney | $274,800 | |
| Nov 24, 2025 | Yann Echelard | $162,850 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Gilder Gagnon Howe & Co Llc. | CHF607,915 | |
| Dec 31, 2025 | Bridgewater Associates, Lp | CHF14,006,377 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 22,050,045 | Institution | 14.59% | ― |
| Ishares | 16,134,528 | Institution | 10.67% | ― |
| Vanguard | 13,224,508 | Institution | 8.75% | ― |
| Vanguard Index Funds | 10,870,337 | Institution | 7.19% | ― |
| Michael S. Weiss | 9,778,086 | Insider | 6.47% | ― |
| Spdr | 5,494,518 | Institution | 3.64% | ― |
| First Trust | 2,103,340 | Institution | 1.39% | ― |
| Fidelity Salem Street Trust | 1,747,445 | Institution | 1.16% | ― |
| Tiaa-cref Funds | 1,653,525 | Institution | 1.09% | ― |
| Fidelity Concord Street Trust | 1,314,669 | Institution | 0.87% | ― |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 10,870,337 | Institution | 7.19% | ― |
| Fidelity Salem Street Trust | 1,747,445 | Institution | 1.16% | ― |
| Tiaa-cref Funds | 1,653,525 | Institution | 1.09% | ― |
| Fidelity Concord Street Trust | 1,314,669 | Institution | 0.87% | ― |
| Professionally Managed Portfolios | 1,300,000 | Institution | 0.86% | ― |
| Vanguard Explorer Fund | 1,285,751 | Institution | 0.85% | ― |
| T. Rowe Price New Horizons Fund, Inc. | 1,013,200 | Institution | 0.67% | ― |
| Vanguard Scottsdale Funds | 1,005,360 | Institution | 0.67% | ― |
| Manager Directed Portfolios | 933,712 | Institution | 0.62% | ― |
| Vanguard Tax-managed Funds | 879,130 | Institution | 0.58% | ― |
FAQ
Who Owns TG Therapeutics (CH:NKB2)?
According to the latest TipRanks data, approximately 52.03% of the company's stock is held by institutional investors, 7.63% is held by insiders, and 40.34% is held by public companies and individual investors.
What percentage of TG Therapeutics (CH:NKB2) stock is held by institutional investors?
According to the latest TipRanks data, approximately 52.03% of TG Therapeutics (CH:NKB2) stock is held by institutional investors: 20.04% by mutual funds, 27.20% by ETFs and 4.80% by other institutional investors.
What percentage of TG Therapeutics (CH:NKB2) stock is held by retail investors?
According to the latest TipRanks data, approximately 40.34% of TG Therapeutics (CH:NKB2) stock is held by public companies and individual investors.
Who owns the most shares of TG Therapeutics (CH:NKB2)?
BlackRock, Inc. owns the most shares of TG Therapeutics (CH:NKB2).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
